Real‐world outcomes for a digital prescription mobile application for adults with irritable bowel syndrome

Background Mahana™ IBS is a Food and Drug Administration‐cleared prescription mobile application designed to deliver 3 months of gut‐directed cognitive behavioral therapy (CBT) to adults ≥22 years old with irritable bowel syndrome (IBS). We assessed whether gut‐directed CBT delivered digitally improved outcomes in IBS management. Methods We studied users who had a dispensed physician prescription for Mahana™ IBS between August 2021 and August 2023. The primary outcome was change in IBS symptom severity (IBS‐SSS) score. Key Results For the 843 patients, 324 (38%) completed half of the program up to session 5, and 162 (19%) of participants completed the full program up to session 10. Median age was 41 years, median IBS‐SSS was 270 (moderate severity), IBS‐mixed subtype was most common (23%) followed by IBS‐C (20%) and IBS‐D (19%). The change in IBS‐SSS was −81.0 (p =